Spruce Biosciences, Inc. entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., LTD. for the development and commercialization of their product candidate, tildacerfont, for the treatment of congenital adrenal hyperplasia (CAH) in Japan, with potential milestone payments and royalties.